Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
APVO 
Aptevo Therapeutics Inc (APVO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/06/2025: APVO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -54.71% | Avg. Invested days 11 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/06/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.47M USD | Price to earnings Ratio - | 1Y Target Price 420 |
Price to earnings Ratio - | 1Y Target Price 420 | ||
Volume (30-day avg) 278496 | Beta 5.73 | 52 Weeks Range 2.81 - 485.37 | Updated Date 06/19/2025 |
52 Weeks Range 2.81 - 485.37 | Updated Date 06/19/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -250.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -115.99% | Return on Equity (TTM) -1023.93% |
Valuation
Trailing PE - | Forward PE 3.94 | Enterprise Value 5745750 | Price to Sales(TTM) 1.61 |
Enterprise Value 5745750 | Price to Sales(TTM) 1.61 | ||
Enterprise Value to Revenue 0.12 | Enterprise Value to EBITDA 0.39 | Shares Outstanding 675000 | Shares Floating 405457 |
Shares Outstanding 675000 | Shares Floating 405457 | ||
Percent Insiders 3.11 | Percent Institutions 3.31 |
Analyst Ratings
Rating 4 | Target Price 420 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Aptevo Therapeutics Inc
Company Overview
History and Background
Aptevo Therapeutics Inc. was founded in 2016 as a spin-off from Emergent BioSolutions. It focuses on developing novel immunotherapies for oncology and hematology. The company leverages its ADAPTIR and ADAPTIR-FLEX platforms to generate bispecific and multi-specific antibody therapeutics.
Core Business Areas
- Oncology: Development of immunotherapeutic candidates for the treatment of various cancers, utilizing the ADAPTIR platform to target specific tumor antigens.
- Hematology: Development of therapies for hematological malignancies and other blood disorders, employing multi-specific antibodies to enhance immune responses.
- ADAPTIR Platform: Licensing and development of therapies based on the ADAPTIR modular protein technology platform.
Leadership and Structure
Marvin L. White is the President and CEO. The company has a Board of Directors overseeing its operations and strategic direction. The organizational structure is divided into research and development, clinical operations, and administrative functions.
Top Products and Market Share
Key Offerings
- Apexigen (rusfertide): Aptevo receives royalties from Acceleron Pharma (acquired by Merck) for net sales of Reblozyl for the treatment of anemia in certain rare blood disorders. The main competitors are other anemia therapies.
- ADAPTIR Platform: The ADAPTIR platform is used to develop novel antibody therapeutics, with potential applications in various diseases. The main competitors for this platform are other antibody engineering platforms like those from Regeneron, Genmab and others.
Market Dynamics
Industry Overview
The biopharmaceutical industry is experiencing rapid growth, driven by advancements in immunotherapy and targeted therapies. There is high demand for novel treatments for cancer and other diseases.
Positioning
Aptevo Therapeutics Inc. is positioned as a developer of innovative immunotherapies, leveraging its proprietary ADAPTIR platform to create bispecific and multi-specific antibodies. It competes with larger pharmaceutical companies and smaller biotech firms in the oncology and hematology spaces.
Total Addressable Market (TAM)
The total addressable market for cancer immunotherapies is substantial, projected to reach hundreds of billions of dollars. Aptevo is positioned to capture a segment of this market through the development and commercialization of its ADAPTIR-based therapies.
Upturn SWOT Analysis
Strengths
- Proprietary ADAPTIR technology platform
- Potential for developing novel immunotherapies
- Experienced management team
- Collaboration with larger pharmaceutical companies
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on royalties from partnered products
- Clinical trial risks associated with drug development
- No currently marketed products
Opportunities
- Expanding the ADAPTIR platform to new therapeutic areas
- Partnering with larger pharmaceutical companies for development and commercialization
- Securing regulatory approvals for its drug candidates
- Acquisition by a larger company
Threats
- Competition from larger pharmaceutical companies with greater resources
- Clinical trial failures
- Regulatory hurdles
- Patent expirations
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- BMY
- AMGN
- PFE
Competitive Landscape
Aptevo faces intense competition from larger pharmaceutical companies with more resources and established market presence. Its competitive advantage lies in its ADAPTIR platform and potential for developing novel immunotherapies.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Growth has been primarily driven by milestone payments from collaborations and royalties from partnered products.
Future Projections: Future growth depends on the success of its clinical programs and the ability to secure new partnerships.
Recent Initiatives: Focus on advancing clinical programs and expanding the ADAPTIR platform.
Summary
Aptevo Therapeutics is a biotechnology company focused on novel immunotherapies and leverages its ADAPTIR platform. Its limited financial resources and dependence on collaboration revenue pose challenges. Success hinges on clinical trial outcomes and establishing new partnerships. The company's future relies on the successful development of its ADAPTIR-based therapies and strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aptevo Therapeutics Inc
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2016-07-20 | President, CEO & Director Mr. Marvin L. White | ||
Sector Healthcare | Industry Biotechnology | Full time employees 37 | Website https://aptevotherapeutics.com |
Full time employees 37 | Website https://aptevotherapeutics.com | ||
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.